Tags: lung | drug | FDA | approval

Glaxo-Theravance Lung Drug Should be Approved, FDA Panel Says

Wednesday, 17 Apr 2013 03:45 PM

GlaxoSmithKline Plc and Theravance Inc.’s Breo should be approved to treat a lung disorder that is the third-leading cause of death in the U.S.

The companies provided substantial evidence the dry powder inhaler can help keep airways open long-term and reduce exacerbations of chronic obstructive pulmonary disease, a panel of Food and Drug Administration advisers voted today in Silver Spring, Maryland. The FDA is expected to decide whether to approve Breo by May 12.

© Copyright 2017 Bloomberg News. All rights reserved.

 
1Like our page
2Share
Companies
GlaxoSmithKline Plc and Theravance Inc.'s Breo should be approved to treat a lung disorder that is the third-leading cause of death in the U.S.
lung,drug,FDA,approval
74
2013-45-17
Wednesday, 17 Apr 2013 03:45 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved